Mode
Text Size
Log in / Sign up

Presbyopia

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Presbyopia

108 trials tracked for Presbyopia: 14 in phase 3 or 4 and 4 with published results. The most-cited published study has 49 citations.

108Trials tracked
14Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 2 Phase 3 12 Phase 2 12 Other / NA 82
  1. Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia Completed · 49 cited
  2. Phase 3 An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-1) Completed · 18 cited
  3. Phase 3 An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2) Completed · 18 cited
  4. Phase 3 A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of Age Completed · 8 cited
  5. Phase 4 Clinical Investigation of the Vision-R800 Device. Completed
  6. Phase 4 The Development of New Functions of Esculin and Digitalis Glycosides Eye Drops: A Study on the Treatment of Presbyopia Completed
Show 44 more trials
  1. Phase 3 A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia Completed
  2. Phase 3 A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily Completed
  3. Phase 3 Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia Completed
  4. Phase 3 Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia Completed
  5. Phase 3 An Evaluation of the Safety of CSF-1 in Presbyopic Subjects Completed
  6. Phase 3 Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia Completed
  7. Phase 3 Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia Completed
  8. Phase 3 Phase 3 Safety Study of LNZ100 and LNZ101 for the Treatment of Presbyopia Subjects Completed
  9. Phase 2 Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia Completed
  10. Phase 2 Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia Completed
  11. Phase 2 Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia Completed
  12. Phase 2 A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia. Completed
  13. Phase 2 A Multi-Center, Double-Masked Evaluation of the Efficacy and Safety of CSF-1 in the Treatment of Presbyopia Completed
  14. Phase 2 A Study to Evaluate the Safety and Efficacy of EV06 Ophthalmic Solution in Improving Vision in Subjects With Presbyopia Completed
  15. Phase 2 Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia Completed
  16. Phase 2 A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia Completed
  17. Phase 2 A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia Completed
  18. Phase 2 A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia Completed
  19. Phase 2 Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia Completed
  20. Phase 2 Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia Completed
  21. N/A Comparison of a Multifocal Contact Lens to a Traditional Multifocal Contact Lens Completed
  22. N/A Comparison of Two Soft Bifocal Contact Lenses Completed
  23. N/A Performance Evaluation of Different Daily Disposable Multifocal Contact Lenses Completed
  24. N/A Silicone Hydrogel Contact Lens Clinical and Comfort Benefits With a Multi-Purpose Disinfecting Solution Completed
  25. N/A Tecnis ZLB00 & Symfony Intraocular Lens Combination Outcomes Completed
  26. N/A Monofocal IOL Visual Outcomes When Targeting Mini Monovision Completed
  27. N/A Prospective Study of Lens Performance of a Monthly Replacement Lens at Two Weeks and Four Weeks Completed
  28. N/A Clinical Performance of a Phakic Intraocular Lens (IOL) Completed
  29. N/A Vivity IOL: Emmetropia Compared to Monovision. Completed
  30. N/A Clinical Evaluation of Two New Silicone Hydrogel Multifocal Products Completed
  31. N/A Clinical Validation Study of Comfilcon A Multifocal Toric Contact Lenses Completed
  32. N/A Assessing the Clinical Performance of Two Frequent Replacement Silicone Hydrogel Multifocal Contact Lenses Completed
  33. N/A Evaluating the Success of Habitual Multifocal Wearers When Refit With a New Lens Design Completed
  34. N/A Safety and Effectiveness Study of the AcuFocus Corneal Inlay ACI 7000PDT in Presbyopes Completed
  35. N/A Clinical Evaluation of the Safety and Efficacy of a New Multifocal Contact Lens Completed
  36. N/A A Dispensing Clinical Trial of Comfilcon A Extended Range Multifocal Lenses Completed
  37. N/A Clinical Assessment of a Multifocal Contact Lens for People Who Use Reading Glasses Only Completed
  38. N/A Post Approval Study of the AcrySof® IQ ReSTOR® Toric IOLs Completed
  39. N/A Multifocal High ADD Contact Lens Proof of Concept Trial Completed
  40. N/A Evaluation of Soft Multifocal Lenses in Presbyopic Previous Contact Lens Wearers Completed
  41. N/A Presbyopia Screening by Community Health Worker in Bangladesh Completed
  42. N/A Clinical Evaluation of Investigational Multifocal Toric Contact Lenses Completed
  43. N/A Long Term Follow-up of the VisAbility™ Micro Insert System for Presbyopic Patients Completed
  44. N/A Evaluation of an Investigational Multifocal Lens Completed

Showing the 50 most-cited and recently-updated of 108 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Presbyopia: what the trials found

Several pharmacological interventions have demonstrated statistically significant improvements in near vision for presbyopia. The Aceclidine and Brimonidine combination ophthalmic solution consistently showed high success rates, with 56% to 74% of participants achieving a ≥3-line improvement in near vision without significant loss in distance vision [18, 19]. Similarly, CSF-1 demonstrated significant improvements in BDCVA at 40cm; notably, dose 2 showed an 80% success rate compared to 64% for dose 1 9, and another trial confirmed a statistically significant gain of ≥3 lines in BDCVA 22.

Phentolamine Ophthalmic Solution 0.75% was shown to result in a significant proportion of subjects achieving ≥15 letters of improvement in photopic binocular DCNVA 13. BRIMOCHOL™ PF also demonstrated statistically significant results, with approximately 49.4% of subjects achieving a ≥15-letter gain without significant loss in near visual acuity 14.

Pilocarpine HCl showed mixed results regarding the duration and consistency of improvement. While some trials reported significantly higher rates of gaining 3 lines or more in DCNVA compared to placebo at certain intervals, the significance was not maintained across all time points (e.g., 6-hour and 8-hour marks) [15, 16]. Additionally, AGN-190584 showed a statistically significant improvement in overall composite driving scores approximately one hour after instillation 11.

Recent results — preliminary, needs further review

  • AcrySof IQ PanOptix IOL Toric 6
  • CPO Pro IOL 6

For the clinician treating this condition

  • Aceclidine and Brimonidine combination therapy shows consistent efficacy in improving near vision by ≥3 lines without compromising distance vision.
  • CSF-1 demonstrates significant improvements in BDCVA at 40cm, with evidence suggesting higher success rates following a second dose.
  • Phentolamine and BRIMOCHOL™ PF are established options for achieving significant gains in photopic binocular DCNVA.

AI synthesis of 6 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.